Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 20;210(11):1763–1771. doi: 10.1093/infdis/jiu337

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

PMC Copyright notice

Figure 3. — Serum antibody responses to the vaccine containing 50 μg of norovirus GI.1 virus-like particle (VLP) and 50 μg of consensus norovirus GII.4 VLP in 18–49 year olds (cohorts A and D), 50–64 year olds (cohort B), and 65–85 year olds (cohort C). Placebo recipients are combined across all cohorts. Subjects received 2 doses of vaccine separated by 28 days (day 0 and day 28). Geometric mean titers (GMTs) of antibody are shown to GI.1 (A, C, E) and GII.4 consensus (B, D, F) VLPs as assessed by total immunoglobulin (A and B), immunoglobulin G (C and D), and immunoglobulin A (E and F) immunoassays.